|Healthcare Review: Chelsea Therapeutics, CombiMatrix, Dara Biosciences, Merck, Galena|
|By Staff and Wire Reports|
|Thursday, 13 March 2014 13:41|
Shares of Chelsea Therapeutics ($CHTP) pop as rumors persist that the company will be acquired or will engage a partner to commercialize Northera. The FDA approved the drug on February 18.
SA contributor Richard Pearson publishes his investigation into Galena ($GALE) and CytRx's ($CYTR) relationship with The Dream Team Group. He concludes that management has had a central role in reviewing and editing numerous bullish articles published on financial websites under various aliases.
CombiMatrix ($CBMX) will provide its tests for analyzing miscarriages to American Pathology Partners (AP2), which is creating a nationwide network of anatomic pathology laboratories. The partnership for the chromosomal microarray analysis (CMA) tests is effective immediately and is starting with UniPath, AP2's flagship laboratory in Denver.
Dara Biosciences ($DARA), which provides a liquid version of the Tamoxifen treatment for breast cancer, finds that the adherence of patients to the tablet form "is less than optimal." In a survey, 14% of respondents said they miss two or more Tamoxifen doses a month, while 8% had swallowing difficulties. Seven percent said a liquid version of Tamoxifen would boost their compliance and 22% said they'd be willing to try it.
The number of cattle deaths that could be connected to Merck's ($MRK) Zilmax feed additive may be much higher than the company has reported to the FDA, a study shows. The analysis found that over 3,800 cattle that received Zilmax in 2011-2012 died, with 40-50% of those deaths probably attributable to the drug. A Reuters review showed that over a six-year period, Merck reported that 285 cattle died in the U.S. unexpectedly or were destroyed after being fed Zilmax. Merck raised doubts about the veracity of the new study and expressed confidence in the product even though the company temporarily withdrew it in August.